Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Pulsed Radiofrequency Versus 5% Dextrose Injection in Chronic Plantar Fasciitis

NCT07688876 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-01-01
Last updated
2026-07-07

Condition(s) studied

Chronic Plantar FasciitisChronic Heel PainFoot Pain

Investigational drug(s) / intervention(s)

Ultrasound-Guided Pulsed Radiofrequency TreatmentUltrasound-Guided 5% Dextrose Injection

Ultrasound-Guided Pulsed Radiofrequency Treatment: Ultrasound-guided pulsed radiofrequency treatment will be applied for chronic plantar fasciitis. Participants will be monitored for at least 30 minutes after the procedure for possible adverse events or complications.

Ultrasound-Guided 5% Dextrose Injection: Ultrasound-guided 5% dextrose injection will be applied around the medial calcaneal insertion of the plantar fascia using the peppering technique, with 0.1-0.2 mL administered at each entry point. The treatment will consist of three sessions performed at 3-week intervals.

Study summary

This prospective, two-center, randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided pulsed radiofrequency and 5% dextrose injection in patients with chronic plantar fasciitis. Eligible participants will be randomized into two parallel groups. One group will receive ultrasound-guided pulsed radiofrequency treatment, and the other group will receive ultrasound-guided 5% dextrose injection using the peppering technique. All participants will receive a home-based plantar fascia stretching exercise program. Outcomes will be assessed at baseline, 3 weeks, 6 weeks, and 12 weeks after treatment. The primary outcome will be pain intensity measured by the Numeric Rating Scale. Secondary outcomes will include foot function, activity-related pain, ankle-hindfoot function, and health-related quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of chronic plantar fasciitis based on medical history and physical examination * Heel pain resistant to conservative treatment for at least 12 weeks * Age between 18 and 70 years * Willingness to participate in the study and provide written informed consent Exclusion Criteria: * Congenital or acquired disease that may impair or prevent foot function, such as rheumatoid arthritis, hemiplegia, congenital foot deformity, traumatic foot or leg amputation, or fracture sequelae * Local infection or skin disease at the treatment site * Bleeding disorder or use of anticoagulant medication within the last week * Disease causing mental dysfunction, such as uncontrolled Parkinson disease or Alzheimer disease * Previous surgery for plantar fasciitis * Refusal to participate in the study or inability to provide informed consent * Failure to attend follow-up visits after treatment * Request to withdraw from the study * Pregnancy or suspected pregnancy * Presence of a cardiac pacemaker * History of epilepsy * Active or previous malignancy * Rheumatologic disease

Primary outcome measure(s)

  • Change in Heel Pain Intensity Assessed by Numeric Rating Scale — Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
    Heel pain intensity will be assessed using the Numeric Rating Scale. Resting pain, pain during plantar fascia stretching, and pain with pressure will be evaluated on an 11-point scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

Trial sites (1)

FacilityCityRegionStatus
Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital Ankara Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07688876 on ClinicalTrials.gov ↗ ← All trials in Turkey